Analyst Michael Matson from Needham reiterated a Buy rating on NeoGenomics and increased the price target to $15.00 from $14.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Matson has given his Buy rating due to a combination of factors, including NeoGenomics’ ability to slightly exceed its preannounced fourth-quarter revenue and deliver EBITDA and EPS that were ahead of market expectations. While overall organic growth eased to about 8% as weakness in the Non-Clinical segment offset strong Clinical gains, the company’s NGS testing business maintained solid momentum with growth in the low-20% range.
Matson also highlights that management’s 2026 revenue and EBITDA outlook generally aligns with Street estimates, suggesting a reasonable level of visibility despite recent volume headwinds from customer consolidation. In addition, the launch of RaDaR ST to biopharma clients and the planned start of clinical RaDaR sales in early 2026, supported by a larger salesforce, underpin a more favorable long-term growth profile, leading him to raise his price target to $15 and reaffirm a positive stance on the shares.